ADMA Biologics ADMA Debt issuance costs and discount amortization
Debt issuance costs and discount amortization at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfDebtDiscountPremium.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's debt issuance costs and discount amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's debt issuance costs and discount amortization?
- ADMA Biologics (ADMA) reported debt issuance costs and discount amortization of $191K in Q1 2026.
- How has ADMA Biologics's debt issuance costs and discount amortization changed year-over-year?
- ADMA Biologics's debt issuance costs and discount amortization increased by 0.5% year-over-year, from $190K to $191K.
- What is the long-term trend for ADMA Biologics's debt issuance costs and discount amortization?
- Over 4 years (2021 to 2025), ADMA Biologics's debt issuance costs and discount amortization has grown at a -21.6% compound annual growth rate (CAGR), from $1.9M to $717K.
- What does debt issuance costs and discount amortization mean?
- The non-cash periodic expense recognized to amortize the discount or issuance costs associated with debt instruments over their term. It effectively adjusts the interest expense to reflect the true effective interest rate of the company's borrowings.